Current Headlines

  1. New 50 Microliter Electronic Pipettes

    INTEGRA has expanded its popular VIAFLO II electronic pipette range. Often requested by users of PCR applications, the new 50 µl models perfectly fill the gap between the 0.5-12.5 µl and  5-125 µl ranges.

  2. PTC Therapeutics Begins Rolling NDA Submission To The FDA For Translarna To Treat Duchenne Muscular Dystrophy

    PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has commenced a rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for Translarna™ for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD)

  3. MRA Applauds Latest Melanoma Drug Approval

    The Melanoma Research Alliance (MRA) recently welcomed news that the U.S. Food & Drug Administration (FDA) has granted approval to Bristol Myers-Squibb’s new immunotherapy drug, Opdivo (nivolumab), for the treatment of metastatic melanoma

  4. Bio-Path Holdings To Initiate Development Of Liposomal Bcl-2 In Follicular Lymphoma

    Bio-Path Holdings, Inc., (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, recently announced that it has initiated development of Liposomal Bcl-2 as a treatment for follicular lymphoma

  5. Harbour Antibodies Announces First U.S. Patent For Novel Transgenic Mouse Antibody Technology For Next Generation Therapeutic Antibody Discovery

    Harbour Antibodies BV announced the issuance of the first U.S. Patent (No. 8,883,150) covering the company’s HCAb mouse platform for producing human “heavy chain only” antibody molecules

  6. Translarna Granted Orphan Drug Designation In The U.S. And Europe For The Treatment Of Mucopolysaccharidosis I

    PTC Therapeutics, Inc. (Nasdaq: PTCT) today announced that both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have granted orphan-drug designation (ODD) to Translarna™ (ataluren) for the treatment of patients with Mucopolysaccharidosis I (MPS I)

  7. Enamine Announces Extension Of Collaboration With Sanofi In Early Drug Discovery

    Enamine Ltd, a leading provider of screening compounds, chemical building blocks and discovery services, has announced that it has extended its collaboration agreement with Sanofi, an integrated global healthcare leader

  8. US Nonprofit Awards Italian Biotech Additional Funding To Study New Class Of Drugs To Treat Alzheimer's Disease

    The Alzheimer's Drug Discovery Foundation (ADDF) and Italian biotechnology company Axxam SpA (Axxam) announced today that the ADDF has awarded a follow-on grant to Axxam to further develop small molecule drugs to treat Alzheimer's disease by targeting inflammation

  9. X-Chem Licenses Cardiovascular Drug Discovery Program To Bayer Pharma AG

    X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, recently announced it has licensed a second drug discovery program to Bayer Pharma AG pursuant to the multi-target collaboration the companies established in July 2012

  10. Novogen Announces Breakthrough Discovery In The Treatment Of Melanoma

    Novogen Limited (ASX:NRT; NASDAQ: NVGN), Australian/US biotechnology company, today announces that it has confirmed that its lead candidate product, TRXE-009, originally developed for the treatment of brain cancers, has been shown in pre-clinical studies also to be highly active against melanoma

Newsletter Signup
Newsletter Signup
Get the latest industry news, insights, and analysis delivered to your inbox.
Join your peers
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.